Loading…
Loading…
VRAY (ViewRay, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
VRAY does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VRAY and 80,000+ other tickers.
See exactly how VRAY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VRAY and 80,000+ other tickers.
ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom. The company's key product, MRIdian, is an MRI-guided radiation therapy solution engineered to address critical concerns during treatment, such as beam distortion and potential skin toxicity. ViewRay's client base spans a diverse range of medical…
WASHINGTON--(BUSINESS WIRE)--In light of ViewRay Systems recent announcement that it would close its doors on October 25, 2023, Dr. Suthanthiran, President/Founder of TeamBest Global Companies (TBG) and Best Cure Foundation, is encouraging all to share their thoughts as to how to preserve, upgrade, innovate, and reduce the cost of technology, service, etc., of ViewRay Systems products—for now and in the future. Suthanthiran has already received numerous inquiries from customers, vendors, and se.
WASHINGTON--(BUSINESS WIRE)--Since the announcement regarding the closing of ViewRay on October 25, 2023, competitors have raced to decommission the ViewRay Systems, replacing them with their own products by establishing relationships with companies that service/decommission/sell refurbished or used equipment—making time of the essence to preserve this valuable technology. While competitors may be motivated to remove ViewRay's systems and offer alternatives, there's a real possibility that the.
WASHINGTON--(BUSINESS WIRE)--Krishnan Suthanthiran offers a solution for continued support and service to ViewRay customers.
DENVER , July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market.
ViewRay (NASDAQ: VRAY ) stock is falling hard on Monday after the MRI company announced its voluntary Chapter 11 bankruptcy filing! According to the company's bankruptcy filing, ViewRay intends to pursue the sale of its business as part of the Chapter 11 process.